Cure My Disease

Don't miss your cure!

 Log in / Sign up

A 30-Minute viral test could spare young children unneeded steroids

NCT ID NCT06580600

Knowledge-focused Sponsor: Queen's University, Belfast Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study tests whether a rapid point-of-care viral test, which gives results in about 30 minutes, can help doctors decide if preschool children with acute wheeze should receive oral steroids. The trial enrolls about 60 children aged 24 to 60 months who come to the emergency department with wheeze and whose need for steroids is unclear. Researchers will randomly assign children to receive steroids based on the test result or not, and will measure how feasible this approach is for a future larger study. The goal is to see if viral triggers can predict which children benefit from steroids, potentially reducing unnecessary side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Point-of-care respiratory virus testing to guide oral corticosteroid use
What this could lead to
If this feasibility study succeeds, it could pave the way for a larger trial that uses rapid viral tests to decide which wheezy preschoolers truly need oral steroids, reducing unnecessary side effects.
What could go wrong
This is a small feasibility study, not a definitive test of effectiveness. It may not show clear benefits, and the approach could fail to improve outcomes in a larger trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

24 to 60 months

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 24-60 months (infants from 24 months +0 days to 60 months + 0 days inclusive) * Clinical diagnosis of acute wheeze * Clinical uncertainty regarding the benefit of OCS as part of patient's standard care Exclusion Criteria: * Signs and symptoms of severe or life-threatening wheeze * Patients presenting with wheeze suspicious for a non - respiratory cause * Clinical evidence of shock or bacterial sepsis * Past history of severe or life-threatening asthma or history of previous PICU admission with acute wheeze * History of preterm birth (before 36+0 weeks gestation) * Known immunodeficiency/ongoing immunosuppressive therapy * Contraindication to oral corticosteroids * Previously enrolled in the PRECISE Study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Wheezing are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Respiratory Sounds

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Wheezing

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Belfast Hospital for Sick Children

    RECRUITING

    Belfast, NI, BT12 6BA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.